Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

DPAG's Associate Professor Mathilda Mommersteeg and Professor Paul Riley, in collaboration with Professor Robin Choudhury from the Radcliffe Department of Medicine, will perform single cell analysis of inflammation during heart regeneration with a grant from the Chan Zuckerberg Initiative.

L-R: Prof Robin Choudhury, Prof Mathilda Mommersteeg and Prof Paul Riley

Cardiovascular disease is the leading cause of death worldwide, with a major contribution from myocardial infarction (MI), also known as a heart attack. Inflammation and ensuing fibrotic scarring on the heart are critical determinants of outcome post heart attack. 

A key, but elusive, therapeutic goal for scientists is to modulate inflammation and scarring, while enhancing normal healing. The cardiac scar that forms in the human heart after heart attack is permanent, so the heart is not able to pump as efficiently as before injury, eventually leading to heart failure. However, remarkably, some fish and neonatal mice do not scar after injury, but instead regenerate functional heart tissue. Inflammatory cells are essential for this regeneration, though their precise role is not understood. 

DPAG's Associate Professor Mathilda Mommersteeg and Professor Paul Riley, together with Professor Robin Choudhury from the Radcliffe Department of Medicine, have received funding from the Chan Zuckerberg Foundation to study the role of inflammatory cells in regenerative versus non-regenerative models post-myocardial infarction using single cell RNA sequencing (SC-Seq) and computational biology.

This grant is part of a new Initiative supporting 29 interdisciplinary teams to build a network of researchers exploring emerging ideas on the role of inflammation in disease. The teams will carry out two-year pilot projects focused on tissue-level inflammatory processes in diverse tissues and disease states.

Head of Science at the Chan Zuckerberg Initiative (CZI) Cori Bargmann said: "Knowing more about inflammation at the level of affected cells and tissues will increase our understanding of many diseases and improve our ability to cure, prevent, or manage them."

More information on the CZI and its funded projects can be found here.

Similar stories

New target identified to develop treatment for Abdominal Aortic Aneurysm

CRM Publication

A new study from the Smart group has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.

Travels with Vignesh

CRM General

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.

Genetic breakthrough to target care for deadly heart condition

CRE Research

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.